Carboplatin

Generic Name
Carboplatin
Brand Names
Paraplatin
Drug Type
Small Molecule
Chemical Formula
C6H12N2O4Pt
CAS Number
41575-94-4
Unique Ingredient Identifier
BG3F62OND5
Background

Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.

Carboplatin was granted FDA approval on 3 March 1989.

Indication

Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.

Associated Conditions
Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma
Associated Therapies
Conditioning regimens for allogeneic stem cell transplantation therapy
Clinical Trials
Related News

Patient-reported Outcomes in Preoperative Immunochemotherapy/Radiotherapy-treated Esophageal Cancer Patients

First Posted Date
2022-10-27
Last Posted Date
2022-11-28
Lead Sponsor
Guangdong Provincial People's Hospital
Target Recruit Count
50
Registration Number
NCT05596890
Locations
🇨🇳

Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China

Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy

First Posted Date
2022-10-17
Last Posted Date
2024-08-06
Lead Sponsor
Fudan University
Target Recruit Count
716
Registration Number
NCT05582499
Locations
🇨🇳

Fudan University Shanghai Cancer Center Shanghai, China, 200032, Shanghai, Shanghai, China

Intestinal Microbiota Impact for Prognosis and Treatment Outcomes in Early Luminal Breast Cancer and Pancreatic Cancer Patients

First Posted Date
2022-10-14
Last Posted Date
2022-10-14
Lead Sponsor
Moscow Clinical Scientific Center
Target Recruit Count
35
Registration Number
NCT05580887
Locations
🇷🇺

Moscow Clinical Scientific Center named after AS Loginov, Moscow, Not Required, Russian Federation

Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer

First Posted Date
2022-10-13
Last Posted Date
2024-12-18
Lead Sponsor
BeiGene
Target Recruit Count
121
Registration Number
NCT05577702
Locations
🇨🇳

Hwa Mei Hospital, University of Chinese Academy of Sciences (Ningbo No Hospital), Ningbo, Zhejiang, China

🇨🇳

The First Affiliated Hospital of Wannan Medical College, Wuhu, Anhui, China

🇨🇳

Beijing Cancer Hospital, Beijing, Beijing, China

and more 11 locations

Pembrolizumab, Carboplatin and Cabazitaxel in Aggressive Metastatic Castration Resistant Prostate Cancer (PEAPOD_FOS)

First Posted Date
2022-10-03
Last Posted Date
2024-06-11
Lead Sponsor
Fundacion Oncosur
Target Recruit Count
42
Registration Number
NCT05563558
Locations
🇪🇸

Hospital Universitario 12 de Octubre, Madrid, Spain

Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)

First Posted Date
2022-09-27
Last Posted Date
2024-11-12
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
1170
Registration Number
NCT05555732
Locations
🇺🇸

Florida Cancer Specialists-North, Saint Petersburg, Florida, United States

🇯🇵

Osaka International Cancer Institute, Osaka, Japan

🇺🇸

Southern Cancer Center Pc, Daphne, Alabama, United States

and more 206 locations

Envafolimab Combined With Chemotherapy in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma

First Posted Date
2022-09-23
Last Posted Date
2022-09-23
Lead Sponsor
Tao Jiang
Target Recruit Count
40
Registration Number
NCT05552651

A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer

First Posted Date
2022-09-16
Last Posted Date
2024-10-21
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
36
Registration Number
NCT05543629
Locations
🇺🇸

University of Cincinnati Medical Center, Cincinnati, Ohio, United States

🇺🇸

Mayo Clinic in Arizona - Phoenix, Phoenix, Arizona, United States

🇺🇸

Local Institution - 0096, Costa Mesa, California, United States

and more 29 locations

A Study of Decreasing Radiation Therapy and Chemotherapy in People With Head and Neck Cancer

First Posted Date
2022-09-16
Last Posted Date
2024-04-26
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
36
Registration Number
NCT05544136
Locations
🇺🇸

Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States

🇺🇸

Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States

🇺🇸

Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States

and more 3 locations

Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma

First Posted Date
2022-09-10
Last Posted Date
2024-10-29
Lead Sponsor
St. Jude Children's Research Hospital
Target Recruit Count
120
Registration Number
NCT05535166
Locations
🇺🇸

Primary Children's Hospital, Salt Lake City, Utah, United States

🇺🇸

Lucille Packard Children's Hospital at Stanford University, Palo Alto, California, United States

🇺🇸

Orlando Health Arnold Palmer Hospital for Children, Orlando, Florida, United States

and more 7 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy